ESTRO meets Asia 2024 - Abstract Book

S272

Interdisciplinary – Upper GI

ESTRO meets Asia 2024

133

Proffered Paper

Neoadjuvant immuno-chemoradiation in esophageal cancer: an individual patient data meta-analysis

Yunsong Liu 1 , Yongxing Bao 1 , Yang Wang 2 , Zeliang Ma 1 , Yu Men 3 , Jianjun Qin 4 , Liyan Xue 5 , Jun Wang 6 , Zhouguang Hui 3 1 Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2 Department of Mathematics & Statistics, Lancaster University, Lancaster, United Kingdom. 3 Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 4 Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 5 Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 6 Department of Radiotherapy, the Fourth Hospital of Hebei Medical University, Shijianzhuang, China

Purpose/Objective:

The investigation of immunotherapy combined with chemoradiation (nICRT) for resectable esophageal cancer is a focal point of interest in clinical research. However, there is a lack of comprehensive systematic analyses of these emerging studies. This meta-analysis aimed to assess the short-term efficacy, safety and survival outcomes of nICRT in esophageal cancer.

Material/Methods:

A systematic search across PubMed, Embase, Cochrane Library and conferences was conducted for studies published until August 15, 2023. Inclusion criteria were studies on resectable esophageal cancer treated with nICRT. Data on pathological complete response (pCR), major pathological response (MPR), treatment-related adverse events (TRAEs), overall survival (OS), and disease-free survival (DFS) were extracted and analyzed. If heterogeneity was substantial (I² statistic >50%), a random-effects model was utilized; otherwise, the common effects model was applied.

Results:

Sixteen studies involving 494 patients were included. The pooled pCR rate was 38% (95% CI, 30-47%; I 2 = 68%). The MPR rate was 74% (95% CI, 65-81%; I 2 = 54%). The incidence of ≥ grade 3 TRAEs was 53% (95% CI, 30-76%; I 2 = 86%). The 1-year and 2-year OS rates were 83.8% (95% CI, 79.6-88.3%) and 65.2% (95% CI, 59.4-71.6%), respectively. The 1-year and 2-year DFS rates were 74.7% (95% CI, 69.7-80.0%) and 52.6% (95% CI, 46.5-59.6%), respectively. Subgroup analyses showed higher pCR (p<0.001) and MPR (p<0.001) for squamous cell carcinoma compared to adenocarcinoma, but similar survival outcomes.

Conclusion: